<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="of COVID-19. Abstract Coronavirus disease-19 (COVID-19) is caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is closely related"/>
 <result pre="COVID-19. Abstract Coronavirus disease-19 (COVID-19) is caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is closely related to"/>
 <result pre="Abstract Coronavirus disease-19 (COVID-19) is caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is closely related to two"/>
 <result pre="SARS-CoV-2 is closely related to two other coronaviruses that caused" exact="disease" post="epidemic breakouts in humans in the last 2 decades,"/>
 <result pre="breakouts in humans in the last 2 decades, namely, severe" exact="acute" post="respiratory distress syndrome coronavirus (SARS-CoV) and Middle East respiratory"/>
 <result pre="in humans in the last 2 decades, namely, severe acute" exact="respiratory" post="distress syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome"/>
 <result pre="in the last 2 decades, namely, severe acute respiratory distress" exact="syndrome" post="coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV)."/>
 <result pre="severe acute respiratory distress syndrome coronavirus (SARS-CoV) and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV). The similarities have enabled the scientists"/>
 <result pre="acute respiratory distress syndrome coronavirus (SARS-CoV) and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV). The similarities have enabled the scientists to"/>
 <result pre="of antibodies to prevent virus entry, nucleotide analogues to prevent" exact="viral" post="replication, and inhibitors of proteases to prevent virion formation,"/>
 <result pre="among others, are being tested for their clinical efficacy. Likewise," exact="complete" post="sequencing of the SARS-CoV-2 and identification of its structural"/>
 <result pre="development of RNA-, DNA-, and peptide-based vaccines as well attenuated" exact="viral" post="vaccines to instigate the host-immune responses. The clinical impacts"/>
 <result pre="has become a pandemic with a colossal global impact. The" exact="disease" post="is caused by a coronavirus called severe acute respiratory"/>
 <result pre="impact. The disease is caused by a coronavirus called severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. COVID-19 along with"/>
 <result pre="The disease is caused by a coronavirus called severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) [1]. COVID-19 along with severe"/>
 <result pre="disease is caused by a coronavirus called severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) [1]. COVID-19 along with severe acute"/>
 <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. COVID-19 along with severe" exact="acute" post="respiratory distress syndrome (SARS) and Middle East respiratory syndrome"/>
 <result pre="syndrome coronavirus 2 (SARS-CoV-2) [1]. COVID-19 along with severe acute" exact="respiratory" post="distress syndrome (SARS) and Middle East respiratory syndrome (MERS)"/>
 <result pre="2 (SARS-CoV-2) [1]. COVID-19 along with severe acute respiratory distress" exact="syndrome" post="(SARS) and Middle East respiratory syndrome (MERS) are the"/>
 <result pre="with severe acute respiratory distress syndrome (SARS) and Middle East" exact="respiratory" post="syndrome (MERS) are the third epidemic outbreaks caused by"/>
 <result pre="severe acute respiratory distress syndrome (SARS) and Middle East respiratory" exact="syndrome" post="(MERS) are the third epidemic outbreaks caused by coronaviruses"/>
 <result pre="of the virus and its modus operandi for replication and" exact="infection" post="of the host cells have been reasonably well-characterized. This"/>
 <result pre="(NCBI Reference Sequence: NC_045512) [2]. The genome codes for the" exact="viral" post="proteome, comprised of four major structural surface glycoproteins, namely,"/>
 <result pre="are generated from cleavage of two large polypeptides [3]. The" exact="viral" post="genome also contains several additional ORFs, which encode the"/>
 <result pre="subsequently excreted via secretory vesicles. The excess load of the" exact="viral" post="proteins during infection with SARS-CoV-2 could overwhelm the ER"/>
 <result pre="secretory vesicles. The excess load of the viral proteins during" exact="infection" post="with SARS-CoV-2 could overwhelm the ER leading to ER"/>
 <result pre="protein (~46 kDa, ~420 amino acid) directly interacts with the" exact="viral" post="RNA as well as the membrane proteins, such as"/>
 <result pre="M protein, and forms nucleocapsid, which provides stability to the" exact="viral" post="genome within the envelope. It also enables viral replication."/>
 <result pre="to the viral genome within the envelope. It also enables" exact="viral" post="replication. The E protein (~ 10 kDa, ~75 amino"/>
 <result pre="is the smallest of the structural proteins and contributes to" exact="viral" post="production and maturation, as its absence significantly reduces viral"/>
 <result pre="to viral production and maturation, as its absence significantly reduces" exact="viral" post="titers and leads to production of incompetent viral particles"/>
 <result pre="significantly reduces viral titers and leads to production of incompetent" exact="viral" post="particles [6]. These structural proteins not only interact with"/>
 <result pre="are collectively responsible for part of the phenotypic effects of" exact="infection" post="with SARS-CoV-2. Fig. 1 Various steps (numbered) involved in"/>
 <result pre="to ACE2 receptors on host cell membrane 2. Integration of" exact="viral" post="S protein with host cell membrane 3. Viral entry"/>
 <result pre="Integration of viral S protein with host cell membrane 3." exact="Viral" post="entry through endocytosis 4. Release of the virus from"/>
 <result pre="cell cytoplasm 5. Formation of replicase-transcriptase complex 6. Synthesis of" exact="viral" post="RNA 7. Translation of viral RNA into large polypeptides"/>
 <result pre="replicase-transcriptase complex 6. Synthesis of viral RNA 7. Translation of" exact="viral" post="RNA into large polypeptides 8. Proteolytic cleavage of viral"/>
 <result pre="of viral RNA into large polypeptides 8. Proteolytic cleavage of" exact="viral" post="proteins into non-structural proteins 9. Translation of viral mRNAs"/>
 <result pre="cleavage of viral proteins into non-structural proteins 9. Translation of" exact="viral" post="mRNAs into structural proteins 10. Assembly of viral RNA"/>
 <result pre="Translation of viral mRNAs into structural proteins 10. Assembly of" exact="viral" post="RNA and proteins into virions at endoplasmic reticulum and"/>
 <result pre="newly formed virion from the host cell by exocytosis. The" exact="viral" post="genome also codes for 16 NSPs, which are involved"/>
 <result pre="codes for 16 NSPs, which are involved not only in" exact="viral" post="replication but also in suppression of the host defenses"/>
 <result pre="impact various biological effects [7]. Through meticulous cooperative interactions, the" exact="viral" post="proteins confer the virus the ability to replicate effectively"/>
 <result pre="the virus the ability to replicate effectively by copying the" exact="viral" post="RNA, evading detection by the host-immune system, and destroying"/>
 <result pre="Several of these NSPs, because of their essential functions in" exact="viral" post="survival and infectivity, are subject to specific therapeutic targeting."/>
 <result pre="gives the virus its crown, is critical for initiating the" exact="viral" post="entry into the host cell (Fig.Â 1). The S"/>
 <result pre="to angiotensin 1-7, the latter with potential beneficial effects on" exact="cardiovascular" post="system [9]. The affinity of the S protein of"/>
 <result pre="of the S protein binds to the ACE2, initiating the" exact="viral" post="entry into the host cell. The successful viral entry"/>
 <result pre="initiating the viral entry into the host cell. The successful" exact="viral" post="entry after attachment of the RBD of S protein"/>
 <result pre="the S1/ACE2 protein complex are considered a critical stage in" exact="viral" post="entry, as inhibition of TMPRSS2 with serine protease inhibitor"/>
 <result pre="protease inhibitor camostat mesylate blocks entry of SARS-CoV-2 into the" exact="epithelial" post="cells [12]. TMPRSS2 also cleaves the ACE2 receptor, which"/>
 <result pre="a candidate to proteolytically modify the S protein and enhance" exact="viral" post="entry into the host cell [10, 11]. Subsequent to"/>
 <result pre="of the virus by endocytosis, and subsequent release of the" exact="viral" post="RNA into host cell cytoplasm. The canonical endocytic pathway"/>
 <result pre="proteases on the same cell type is considered essential for" exact="infection" post="with SARS-CoV-2. Data in the Human Protein Atlas (https://www.proteinatlas.org/)"/>
 <result pre="considered essential for infection with SARS-CoV-2. Data in the Human" exact="Protein" post="Atlas (https://www.proteinatlas.org/) show that ACE2 is abundantly expressed in"/>
 <result pre="Protein Atlas (https://www.proteinatlas.org/) show that ACE2 is abundantly expressed in" exact="type II" post="alveolar cells in the lung, nasal, and bronchial epithelial"/>
 <result pre="type II alveolar cells in the lung, nasal, and bronchial" exact="epithelial" post="cells, as well as in the epithelial cells in"/>
 <result pre="nasal, and bronchial epithelial cells, as well as in the" exact="epithelial" post="cells in the gastrointestinal tract (duodenum and small intestine),"/>
 <result pre="or harmful effects of induction of interferons in response to" exact="infection" post="with SARS-CoV-2 [14]. TMPRSS2 is expressed in the alveolar"/>
 <result pre="infection with SARS-CoV-2 [14]. TMPRSS2 is expressed in the alveolar" exact="type II" post="cells, gastrointestinal tract, kidney, epididymis, prostate, pancreas, and parathyroid"/>
 <result pre="provides a plausible explanation for the predominant involvement of the" exact="respiratory" post="system in COVID-19. Upon release into the host cell"/>
 <result pre="in COVID-19. Upon release into the host cell cytoplasm, the" exact="viral" post="RNA recruits the host's translational ribosomes to synthesize various"/>
 <result pre="viral RNA recruits the host's translational ribosomes to synthesize various" exact="viral" post="proteins necessary for its replication. Two large polypeptide chains"/>
 <result pre="its replication. Two large polypeptide chains are expressed from the" exact="viral" post="RNA, which are then cleaved into NSPs, including RNA-dependent"/>
 <result pre="cleaved into NSPs, including RNA-dependent RNA polymerase. A combination of" exact="viral" post="and host proteins, referred to as the replicase-transcriptase complex,"/>
 <result pre="replicase-transcriptase complex, is formed, which mediates synthesis of the new" exact="viral" post="RNA and expression of the structural proteins, including the"/>
 <result pre="of the structural proteins, including the nucleocapsid. The newly synthesized" exact="viral" post="RNA and the structural proteins are assembled in the"/>
 <result pre="virions. The ER-Golgi system also processes formation of the secretory" exact="viral" post="vesicles and subsequent export of the newly formed viruses"/>
 <result pre="through exocytosis. 4 A primer on host-immune response to SARS-CoV-2" exact="infection" post="SARS viruses utilize a number of mechanisms to evade"/>
 <result pre="the Toll-like receptors to recognize the pathogen-associated molecular pattern on" exact="viral" post="proteins and instigate the host-immune responses. The recognition, through"/>
 <result pre="of the proinflammatory cytokines and chemokines, such as IL6 and" exact="tumor" post="necrosis factor a (TNFa) and MCP1 (reviewed in [17])."/>
 <result pre="events predominantly occur in the lungs but largely because of" exact="systemic" post="effects of the cytokines and chemokines, other organs, including"/>
 <result pre="effects of the cytokines and chemokines, other organs, including the" exact="heart" post="are also involved. In accord with the important role"/>
 <result pre="and chemokines have been associated with the severity of the" exact="disease" post="and the clinical outcomes in patients with COVID-19 [18]."/>
 <result pre="prompting generation of antibodies. These antibodies are specific to the" exact="viral" post="proteins and are comprised of IgM and IgG. Whereas"/>
 <result pre="The virus is transmitted from person to person via airborne" exact="respiratory" post="droplets and aerosols. SARS-CoV-2 is more contagious but less"/>
 <result pre="COVID-19, including age, biological sex, pre-existing medical conditions, such as" exact="cardiovascular disease," post="diabetes, and obesity. Otherwise, the reasons for: inter-individual variability"/>
 <result pre="biological sex, pre-existing medical conditions, such as cardiovascular disease, diabetes," exact="and obesity." post="Otherwise, the reasons for: inter-individual variability in susceptibility to"/>
 <result pre="diabetes, and obesity. Otherwise, the reasons for: inter-individual variability in" exact="susceptibility to" post="SARS-CoV-2, which ranges from an asymptomatic course to that"/>
 <result pre="which ranges from an asymptomatic course to that of severe" exact="disease" post="requiring intubation, are largely unknown. The variability likely reflects"/>
 <result pre="complex stochastic interactions among multiple factors, including possible exposure load," exact="viral" post="shedding, pre-existing neutralizing antibodies that cross-react with SARS-CoV-2 proteins,"/>
 <result pre="in the human leukocyte antigens (HLA) is implicated in affecting" exact="susceptibility to" post="SARS-CoV-2 and severity of COVID-19 [23]. The majority of"/>
 <result pre="who are diagnosed with COVID-19 are minimally or mildly symptomatic." exact="Viral" post="shedding may occur about 3 days before development of"/>
 <result pre="smell (anosmia), sore throat, rhinorrhea, nausea, vomiting, and diarrhea. The" exact="disease" post="is self-limiting in the majority of patients but about"/>
 <result pre="in those with comorbid conditions. About 5% of the infected" exact="symptomatic" post="patients develop acute respiratory distress syndrome and require oxygen"/>
 <result pre="comorbid conditions. About 5% of the infected symptomatic patients develop" exact="acute" post="respiratory distress syndrome and require oxygen supplementation through intubation"/>
 <result pre="conditions. About 5% of the infected symptomatic patients develop acute" exact="respiratory" post="distress syndrome and require oxygen supplementation through intubation and"/>
 <result pre="5% of the infected symptomatic patients develop acute respiratory distress" exact="syndrome" post="and require oxygen supplementation through intubation and other invasive"/>
 <result pre="supplementation through intubation and other invasive procedures. Lungs are the" exact="primary" post="organ involved but involvement of other organs, mostly indirectly"/>
 <result pre="mostly indirectly because of cytokine storms is not uncommon. The" exact="heart" post="is involved in about 20% of the cases, as"/>
 <result pre="ejection fraction on echocardiography. Direct cardiac involvement is less certain." exact="Cardiac" post="involvement is a major determinant of clinical outcomes in"/>
 <result pre="in patients with COVID-19. In advanced cases multi-organ failure, including" exact="coagulopathy" post="and lymphopenia, develops and progresses to death. The overall"/>
 <result pre="lymphopenia, develops and progresses to death. The overall case-fatality of" exact="symptomatic" post="patients with COVID-19 varies with age and is highest"/>
 <result pre="by testing alone (reverse-transcriptase polymerase chain testing alone), which includes" exact="symptomatic" post="and asymptomatic individuals. The overall mortality varies from less"/>
 <result pre="intubation [24,25]. A number of factors are implicated in increased" exact="susceptibility to" post="COVID-19 and its clinical outcomes, including aging and comorbid"/>
 <result pre="its clinical outcomes, including aging and comorbid conditions. Elderly with" exact="diabetes" post="and cardiovascular diseases are particularly susceptible. Several factors are"/>
 <result pre="outcomes, including aging and comorbid conditions. Elderly with diabetes and" exact="cardiovascular" post="diseases are particularly susceptible. Several factors are implicated in"/>
 <result pre="discussed above and partly because of the presence of concomitant" exact="cardiovascular" post="diseases, diabetes mellitus and others. Although males and females"/>
 <result pre="and partly because of the presence of concomitant cardiovascular diseases," exact="diabetes mellitus" post="and others. Although males and females are equally susceptible"/>
 <result pre="and others. Although males and females are equally susceptible to" exact="infection" post="with SARS-CoV-2, there is a sex-dependent difference in the"/>
 <result pre="hormones on expression of genes involved in immunity, Y- and" exact="X-linked" post="genes involved in immunity, nonhomogenous X-chromosome inactivation, and cell"/>
 <result pre="largely determined by the expression of protein constituents involved in" exact="viral" post="entry. Single cell sequencing data show that ACE2 is"/>
 <result pre="levels in other cardiac cell types, including myocytes, fibroblasts, smooth" exact="muscle" post="cells, and endothelial cells [31,32]. In contrast, TMPRSS2 and"/>
 <result pre="and CTSL are expressed at relatively low levels in the" exact="cardiovascular" post="cells [31, 32]. Because tropism of the SARS-CoV-2 depends"/>
 <result pre="the SARS-CoV-2 depends on coexpression of ACE2 and host proteases," exact="viral" post="myocarditis is not a common feature of COVID-19. However,"/>
 <result pre="SARS-CoV-2 depends on coexpression of ACE2 and host proteases, viral" exact="myocarditis" post="is not a common feature of COVID-19. However, histological"/>
 <result pre="histological and magnetic resonance imaging evidence of myocarditis, such as" exact="interstitial fibrosis," post="inflammatory cellular infiltrates, and necrosis, has been reported in"/>
 <result pre="with COVID-19. Whether these changes are the direct consequence of" exact="viral infection" post="or are secondary to increased levels of cytokines, catecholamines,"/>
 <result pre="COVID-19. Whether these changes are the direct consequence of viral" exact="infection" post="or are secondary to increased levels of cytokines, catecholamines,"/>
 <result pre="changes are the direct consequence of viral infection or are" exact="secondary" post="to increased levels of cytokines, catecholamines, or hypoxia, and"/>
 <result pre="myocardial involvement in COVID-19 patients, there are ample data on" exact="secondary" post="involvement of the cardiovascular system, manifesting as elevated blood"/>
 <result pre="patients, there are ample data on secondary involvement of the" exact="cardiovascular" post="system, manifesting as elevated blood levels of cardiac enzymes;"/>
 <result pre="regional and global wall motion abnormalities, cardiac arrhythmias, intravascular thrombosis," exact="and heart" post="failure (reviewed in [33,34,35]). More importantly, concomitant cardiovascular disease"/>
 <result pre="and global wall motion abnormalities, cardiac arrhythmias, intravascular thrombosis, and" exact="heart" post="failure (reviewed in [33,34,35]). More importantly, concomitant cardiovascular disease"/>
 <result pre="thrombosis, and heart failure (reviewed in [33,34,35]). More importantly, concomitant" exact="cardiovascular disease" post="and secondary cardiac involvement are major determinants of clinical"/>
 <result pre="and heart failure (reviewed in [33,34,35]). More importantly, concomitant cardiovascular" exact="disease" post="and secondary cardiac involvement are major determinants of clinical"/>
 <result pre="failure (reviewed in [33,34,35]). More importantly, concomitant cardiovascular disease and" exact="secondary" post="cardiac involvement are major determinants of clinical outcomes, including"/>
 <result pre="patients with COVID-19 [36,37]. Coagulopathy, represented by increased D-Dimer levels," exact="disseminated intravascular coagulation" post="(DIC), and thrombocytopenia, and thrombotic events, is a common"/>
 <result pre="and thrombotic events, is a common manifestation of COVID-19 [38,39]." exact="Increased" post="coagulopathy is in part because of the so-called â€œcytokine"/>
 <result pre="thrombotic events, is a common manifestation of COVID-19 [38,39]. Increased" exact="coagulopathy" post="is in part because of the so-called â€œcytokine stormâ€�"/>
 <result pre="prothrombotic factors [39]. Approximately, 5% of the hospitalized patients experienced" exact="venous thromboembolism," post="and the overall thrombotic complication rate is about 10%"/>
 <result pre="consensus on the proper anticoagulation approach, and the risk of" exact="bleeding" post="is relatively high [40]. Nevertheless, the patients are commonly"/>
 <result pre="the specific components of the virus. Likewise, sequencing of the" exact="viral" post="genome and identification of its proteome have enabled the"/>
 <result pre="have enabled the investigators to develop vaccines by using the" exact="viral" post="RNAs and specific epitopes of the viral proteins as"/>
 <result pre="by using the viral RNAs and specific epitopes of the" exact="viral" post="proteins as antigens. Over 3,000 clinical trials, including ~"/>
 <result pre="number of interventions that directly target specific components pertaining to" exact="viral" post="entry and replication are discussed along with various approaches"/>
 <result pre="along with various approaches to vaccine development. 6.1 Therapies targeting" exact="viral" post="entry Entry of the SARS-CoV-2 into the host cells"/>
 <result pre="cleavage of the S1 subunit and ACE2, binding of the" exact="viral" post="S proteins through the RBD in the S1 subunit"/>
 <result pre="the ACE2 receptors on the host cells, fusion of the" exact="viral" post="S protein with the host cell membrane, and endocytosis"/>
 <result pre="(Fig.Â 1). This is then followed by release of the" exact="viral" post="RNA into host cell cytoplasm and synthesis of viral"/>
 <result pre="the viral RNA into host cell cytoplasm and synthesis of" exact="viral" post="proteins. The newly synthesized viral proteins and viral RNA"/>
 <result pre="cell cytoplasm and synthesis of viral proteins. The newly synthesized" exact="viral" post="proteins and viral RNA are assembled into virions in"/>
 <result pre="synthesis of viral proteins. The newly synthesized viral proteins and" exact="viral" post="RNA are assembled into virions in the ER/Golgi apparatus"/>
 <result pre="of interventions are pursued to target specific steps involved in" exact="viral" post="entry, which are discussed briefly. 6.1.1 Recombinant ACE2 The"/>
 <result pre="is expected to competitively bind and neutralize the ability of" exact="viral" post="S protein to bind to the cellular ACE2 receptors."/>
 <result pre="cellular ACE2 receptors. Consequently, the approach is expected to reduce" exact="viral" post="entry into the host cell and attenuate the phenotypic"/>
 <result pre="plasma, containing neutralizing antibodies, has been used for treatment of" exact="infectious diseases" post="for decades. A neutralizing antibody functions by binding to"/>
 <result pre="antibody functions by binding to a specific domain of the" exact="viral" post="protein or host receptor for the virus, blocking viral"/>
 <result pre="the viral protein or host receptor for the virus, blocking" exact="viral" post="entry into the cell. The main target of neutralizing"/>
 <result pre="which is responsible, after conformational changes and proteolytic modifications, for" exact="viral" post="entry into the host cell through binding to the"/>
 <result pre="produce multiple neutralizing antibodies that target multiple epitopes on the" exact="viral" post="proteins. These antibodies have been extracted, purified, and used"/>
 <result pre="the main function of the neutralizing antibodies is prevention of" exact="viral" post="entry. This is in contrast to nucleoside analogues and"/>
 <result pre="This is in contrast to nucleoside analogues and inhibitors of" exact="viral" post="proteases that target viral replication and virion formation within"/>
 <result pre="to nucleoside analogues and inhibitors of viral proteases that target" exact="viral" post="replication and virion formation within the host cell, respectively."/>
 <result pre="of plasma from patients who have recovered from COVID-19 on" exact="viral" post="load, radiological findings, and survival of patients with severe"/>
 <result pre="In support of the critical role of this protease in" exact="viral" post="entry, data in mice show that deletion of Tmprss2"/>
 <result pre="data in mice show that deletion of Tmprss2 gene abrogates" exact="infection" post="with viruses similar to SARS-CoV-2 [48]. Camostat mesylate and"/>
 <result pre="commercially available and are currently being used for treatment of" exact="chronic" post="pancreatitis and cystic fibrosis, respectively. Preclinical studies show treatment"/>
 <result pre="available and are currently being used for treatment of chronic" exact="pancreatitis" post="and cystic fibrosis, respectively. Preclinical studies show treatment with"/>
 <result pre="are currently being used for treatment of chronic pancreatitis and" exact="cystic fibrosis," post="respectively. Preclinical studies show treatment with camostat mesylate blocks"/>
 <result pre="treatment with camostat mesylate blocks entry of SARS-CoV-2 into the" exact="epithelial" post="cells [12]. Likewise, nafamostat has been reported to reduce"/>
 <result pre="in vitro assay [49]. Clinical evidence in COVID-19 patients is" exact="limited" post="to case reports suggesting clinical efficacy [50]. Potential efficacy"/>
 <result pre="it involves endocytic pathways, which could be targeted to prevent" exact="viral" post="entry. A number of currently available drugs have been"/>
 <result pre="reports on favorable clinical outcomes and the reduction in the" exact="viral" post="load (reviewed in [51]). However, the initial enthusiasm for"/>
 <result pre="treatment of patients with COVID-19 has been dampened in the" exact="absence of" post="compelling clinical evidence of efficacy in the observational data"/>
 <result pre="Table 1 Therapeutic agent Target Mechanism of action Study Design" exact="Primary" post="endpoint: 28-day mortality Dexamethasone (Dexa) General inflammation A steroid"/>
 <result pre="of action Study Design Primary endpoint: 28-day mortality Dexamethasone (Dexa)" exact="General" post="inflammation A steroid Dexa: 6 mg po qd PO"/>
 <result pre="requiring oxygen (95% CI: 0.67-0.96)No benefit in those not requiring" exact="respiratory" post="support Hydroxychloroquine (HCQ) Viral entry by endocytosis Impairs lysosome"/>
 <result pre="0.67-0.96)No benefit in those not requiring respiratory support Hydroxychloroquine (HCQ)" exact="Viral" post="entry by endocytosis Impairs lysosome function HCQ: NÂ =Â"/>
 <result pre="hospital stay or other outcomes Loinavir-Ritonavir (L-R) Protease/cytochrome P450 inhibitors" exact="Viral" post="replication L-R: NÂ =Â 1,596 Usual care: NÂ =Â"/>
 <result pre="L-R: 22.1%Usual care: 21.3%Relative risk: 1.04 (95%CI: 0.91-1.18)No benefit on" exact="secondary" post="endpoints 6.2 Therapies targeting viral replication Replication of SARS-CoV-2"/>
 <result pre="1.04 (95%CI: 0.91-1.18)No benefit on secondary endpoints 6.2 Therapies targeting" exact="viral" post="replication Replication of SARS-CoV-2 requires copying of the viral"/>
 <result pre="targeting viral replication Replication of SARS-CoV-2 requires copying of the" exact="viral" post="RNA to make new strands, synthesis of new viral"/>
 <result pre="the viral RNA to make new strands, synthesis of new" exact="viral" post="protein, including proteolytic cleavage of the large polypeptides into"/>
 <result pre="of the large polypeptides into multiple units, co-assembly of the" exact="viral" post="proteins and RNA to form virions, and processing of"/>
 <result pre="from the host cells (Fig.Â 1). These components involved in" exact="viral" post="replication are potential therapeutic targets, as discussed below. 6.2.1"/>
 <result pre="by nucleoside analogues The approach exploits the rare error of" exact="viral" post="RNA-dependent RNA polymerase during RNA synthesis, resulting in incorporation"/>
 <result pre="RNA synthesis, resulting in incorporation of modified nucleotides into the" exact="viral" post="RNA during synthesis, which leads to premature termination of"/>
 <result pre="which leads to premature termination of RNA elongation, effectively abolishing" exact="viral" post="replication [54]. A library of nucleoside analogues, which were"/>
 <result pre="which were initially developed and approved for treatment of other" exact="viral" post="diseases, such as Ebola virus disease and influenza, are"/>
 <result pre="for treatment of other viral diseases, such as Ebola virus" exact="disease" post="and influenza, are candidates to effectively terminate SARS-CoV-2 replication"/>
 <result pre="triphosphate these nucleosides forms convert to active drugs and terminate" exact="viral" post="RNA synthesis upon incorporation. Among the nucleoside analogues, remdesivir,"/>
 <result pre="for clinical use in patients with COVID-19. Remdesivir incorporates into" exact="viral" post="RNA during synthesis and inhibits replication of the virus."/>
 <result pre="preliminary studies with favipiravir, which targets RNA-dependent RNA polymerase, suggest" exact="partial" post="beneficial effects [60,61]. Several randomized clinical trials (Phase 2"/>
 <result pre="analogue, which inhibits SARS-CoV-2 replication in vitro in human airway" exact="epithelial" post="cells and improved pulmonary pathology in a mouse model"/>
 <result pre="replication in vitro in human airway epithelial cells and improved" exact="pulmonary" post="pathology in a mouse model [62]. Safety, tolerability, and"/>
 <result pre="reverse, in part, the response of the host cells to" exact="infection" post="with SARS-CoV-2. A notable phenotypic feature of COVID-19 is"/>
 <result pre="was found to reduce 28-day mortality modestly in those requiring" exact="respiratory" post="support in the RECOVERY study [69]. Thus far, dexamethasone"/>
 <result pre="ease of manufacturing in large quantity and in high purity," exact="stable" post="storage and transportation, convenient route of administration, absence of"/>
 <result pre="high purity, stable storage and transportation, convenient route of administration," exact="absence of" post="fortuitous adverse effects, and a low cost. Recognizing the"/>
 <result pre="that are essential to demonstrate efficacy of the new vaccines." exact="Multiple" post="approaches to vaccine development are being pursued, which are"/>
 <result pre="Fortuitous immune responseCost Phase 3 DNA-based Vector-based delivery of a" exact="viral" post="gene Easy to generate and stable Storage at room"/>
 <result pre="Vector-based delivery of a viral gene Easy to generate and" exact="stable" post="Storage at room temperatureScalableCellular and humoral responsesTwo or more"/>
 <result pre="type virus Phase 2 Peptide-based A fragment or whole length" exact="viral" post="peptide Non-infectiousRobust immune responseSafeEase of delivery Challenging manufacturingStabilityNeed for"/>
 <result pre="Live attenuated virus De-optimization of the genome (to reduce pathogenicity)" exact="Multiple" post="viral antigensStrong immune response Safety concernsLabor intensive Phase I"/>
 <result pre="attenuated virus De-optimization of the genome (to reduce pathogenicity) Multiple" exact="viral" post="antigensStrong immune response Safety concernsLabor intensive Phase I Inactivated"/>
 <result pre="or UV inactivated virus Relatively simpleStrong immune response Risk of" exact="partial" post="inactivationRisk of becoming pathogenic Phase I Replication fidelity of"/>
 <result pre="be at 2x10âˆ’5[70]. Nevertheless, the rare errors that occur during" exact="viral" post="genome replication could results in generation of variants that"/>
 <result pre="to antigenic drift, and modify the host responses to the" exact="viral" post="antigen, and hence, impede generation of an effective vaccine."/>
 <result pre="G614 variant increases infectivity and is associated with a higher" exact="viral" post="load [71]. Preliminary data suggest that the p.D614G variant"/>
 <result pre="rationale is to deliver an mRNA that codes for a" exact="viral" post="protein as an antigen presented to the host-immune system"/>
 <result pre="against COVID-19 was the mRNA-1273 vaccine, which is a modified" exact="viral" post="RNA encapsulated in a lipid microparticle capsule [75]. A"/>
 <result pre="in a significant number of the recipients [75]. Given the" exact="transient" post="nature of mRNA-induced immunogenicity, repeated injection is often necessary"/>
 <result pre="(SAM) constructs, whereby a replicase mediates prolonged transcription of the" exact="viral" post="mRNA and hence, persistent presentation of the antigen to"/>
 <result pre="a single injection [76]. Likewise, dendritic cells transfected with the" exact="viral" post="RNA could potently activate antigen-specific T cells and confer"/>
 <result pre="vector, such as plasmids, replication-deficient adenoviruses, lentiviruses, or replication-competent vesicular" exact="stomatitis" post="virus, to transfer a SARS-CoV-2 gene and express a"/>
 <result pre="stomatitis virus, to transfer a SARS-CoV-2 gene and express a" exact="viral" post="protein, typically the S protein, to elicit immunogenicity. DNA"/>
 <result pre="high quality at a relatively low cost, relatively safe, and" exact="stable" post="at room temperature. The DNA vaccines could be delivered"/>
 <result pre="and even electroporation. DNA vaccines have been developed for several" exact="infectious diseases" post="and have been shown to be well-tolerated and immunogenic."/>
 <result pre="SARS-CoV-2. Preliminary studies in rhesus macaques upon expression of several" exact="viral" post="S immunogens have shown have humoral and cellular responses,"/>
 <result pre="The immune response following DNA vaccination was effective in reducing" exact="viral" post="RNA levels upon inoculation of the immunized monkeys with"/>
 <result pre="of gene therapy [79,80]. 7.3 Peptide-based vaccines Typically a synthetic" exact="viral" post="peptide or a fusion recombinant peptide is delivered to"/>
 <result pre="in the case of SARS-CoV. To enhance immunogenicity of the" exact="viral" post="peptides, often an adjuvant or an epitope that is"/>
 <result pre="by the T or B cells are fused with the" exact="viral" post="protein. Likewise, multi-epitope peptides might confer a superior immune"/>
 <result pre="A recently developed technique is delivery of a fragment of" exact="viral" post="S protein through microneedle array, as opposed to conventional"/>
 <result pre="injection [81]. Similarly, fusion proteins, comprised of a fragment of" exact="viral" post="S or M protein and an adjuvant, such as"/>
 <result pre="classic antigens for vaccine generation, dating back to vaccination against" exact="smallpox" post="by Edward Jenner who coined the term vaccination. The"/>
 <result pre="to ultraviolet light. In the case of live attenuated virus," exact="viral" post="genome is deoptimize to reduce its pathogenicity while maintaining"/>
 <result pre="to reduce its pathogenicity while maintaining its immunogenicity against multiple" exact="viral" post="antigen. The use of live attenuated or inactivated virus"/>
 <result pre="b-propiolactone) induced an effective immune response, as evidenced by decreased" exact="viral" post="load and protection against infection upon challenge of the"/>
 <result pre="response, as evidenced by decreased viral load and protection against" exact="infection" post="upon challenge of the monkey with SARS-CoV-2 [82]. Inactivated"/>
 <result pre="of diseases. Declaration of competing interest None. References References 1ZhouPYangXLWangXGHuBZhangLZhangWA" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="of probable bat originNature579202027027332015507 2WuFZhaoSYuBChenYMWangWSongZGA new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature579202026526932015508 3BartlamMYangHRaoZStructural insights into SARS coronavirus proteinsCurr"/>
 <result pre="probable bat originNature579202027027332015507 2WuFZhaoSYuBChenYMWangWSongZGA new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature579202026526932015508 3BartlamMYangHRaoZStructural insights into SARS coronavirus proteinsCurr Opin"/>
 <result pre="glycoproteinCell1812020281292e632155444 5ShangJYeGShiKWanYLuoCAiharaHStructural basis of receptor recognition by SARS-CoV-2Nature581202022122432225175 6DeDiegoMLAlvarezEAlmazanFRejasMTLamirandeERobertsAA severe" exact="acute" post="respiratory syndrome coronavirus that lacks the E gene is"/>
 <result pre="5ShangJYeGShiKWanYLuoCAiharaHStructural basis of receptor recognition by SARS-CoV-2Nature581202022122432225175 6DeDiegoMLAlvarezEAlmazanFRejasMTLamirandeERobertsAA severe acute" exact="respiratory" post="syndrome coronavirus that lacks the E gene is attenuated"/>
 <result pre="basis of receptor recognition by SARS-CoV-2Nature581202022122432225175 6DeDiegoMLAlvarezEAlmazanFRejasMTLamirandeERobertsAA severe acute respiratory" exact="syndrome" post="coronavirus that lacks the E gene is attenuated in"/>
 <result pre="drug repurposingNature583202045946832353859 8ToturaALBaricRSSARS coronavirus pathogenesis: host innate immune responses and" exact="viral" post="antagonism of interferonCurr Opin Virol2201226427522572391 9MarianAJ.The discovery of the"/>
 <result pre="only proteolysis by TMPRSS2 augments entry driven by the severe" exact="acute" post="respiratory syndrome coronavirus spike proteinJ Virol8820141293130724227843 14ZieglerCGKAllonSJNyquistSKMbanoIMMiaoVNTzouanasCNSARS-CoV-2 receptor ACE2"/>
 <result pre="proteolysis by TMPRSS2 augments entry driven by the severe acute" exact="respiratory" post="syndrome coronavirus spike proteinJ Virol8820141293130724227843 14ZieglerCGKAllonSJNyquistSKMbanoIMMiaoVNTzouanasCNSARS-CoV-2 receptor ACE2 is"/>
 <result pre="by TMPRSS2 augments entry driven by the severe acute respiratory" exact="syndrome" post="coronavirus spike proteinJ Virol8820141293130724227843 14ZieglerCGKAllonSJNyquistSKMbanoIMMiaoVNTzouanasCNSARS-CoV-2 receptor ACE2 is an"/>
 <result pre="14ZieglerCGKAllonSJNyquistSKMbanoIMMiaoVNTzouanasCNSARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway" exact="epithelial" post="cells and is detected in specific cell subsets across"/>
 <result pre="15LukassenSChuaRLTrefzerTKahnNCSchneiderMAMuleyTSARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial" exact="transient" post="secretory cellsEMBO J392020e105114 16VaaralaMHPorvariKSKellokumpuSKyllonenAPVihkoPTExpression of transmembrane serine protease TMPRSS2"/>
 <result pre="TMPRSS2 in mouse and human tissuesJ Pathol193200113414011169526 17GuzikTJMohiddinSADimarcoAPatelVSavvatisKMarelli-BergFMCOVID-19 and the" exact="cardiovascular" post="system: implications for risk assessment, diagnosis, and treatment optionsCardiovasc"/>
 <result pre="affected countriesJ Infect802020e32ee332209383 20EllinghausDDegenhardtFBujandaLButiMAlbillosAInvernizziPGenomewide association study of severe Covid-19 with" exact="respiratory" post="failureN Engl J Med2020, NEJMoa2020283 21LevantovskyRvan der HeideVShared CD8(+)"/>
 <result pre="print). 22SnyderTMGittelmanRMKlingerMMayDHOsborneEJTaniguchiRMagnitude and dynamics of the T-cell response to SARS-CoV-2" exact="infection" post="at both individual and population levelsmedRxiv.2020, 2020.07.31.20165647 23NguyenADavidJKMadenSKWoodMAWeederBRNelloreAHuman leukocyte"/>
 <result pre="population levelsmedRxiv.2020, 2020.07.31.20165647 23NguyenADavidJKMadenSKWoodMAWeederBRNelloreAHuman leukocyte antigen susceptibility map for severe" exact="acute" post="respiratory syndrome coronavirus 2J Virol94132020e00510e0052032303592 24RichardsonSHirschJSNarasimhanMCrawfordJMMcGinnTDavidsonKWPresenting characteristics, comorbidities, and"/>
 <result pre="levelsmedRxiv.2020, 2020.07.31.20165647 23NguyenADavidJKMadenSKWoodMAWeederBRNelloreAHuman leukocyte antigen susceptibility map for severe acute" exact="respiratory" post="syndrome coronavirus 2J Virol94132020e00510e0052032303592 24RichardsonSHirschJSNarasimhanMCrawfordJMMcGinnTDavidsonKWPresenting characteristics, comorbidities, and outcomes"/>
 <result pre="2020.07.31.20165647 23NguyenADavidJKMadenSKWoodMAWeederBRNelloreAHuman leukocyte antigen susceptibility map for severe acute respiratory" exact="syndrome" post="coronavirus 2J Virol94132020e00510e0052032303592 24RichardsonSHirschJSNarasimhanMCrawfordJMMcGinnTDavidsonKWPresenting characteristics, comorbidities, and outcomes among"/>
 <result pre="in the human heartCardiovasc Res11620201733174132638018 32TuckerNRChaffinMBediKCJr.PapangeliIAkkadADArduiniAMyocyte-specific upregulation of ACE2 in" exact="cardiovascular" post="disease: implications for SARS-CoV-2-mediated myocarditisCirculation142202070871032795091 33AkhmerovAMarbanE.COVID-19 and the heartCirc"/>
 <result pre="Res12620201443145532252591 34BujaLMWolfDAZhaoBAkkantiBMcDonaldMLelenwaLThe emerging spectrum of cardiopulmonary pathology of the coronavirus" exact="disease" post="2019 (COVID-19): report of 3 autopsies from Houston, Texas,"/>
 <result pre="States citiesCardiovasc Pathol482020107233 35BarthRFBujaLMParwaniAVThe spectrum of pathological findings in coronavirus" exact="disease" post="(COVID-19) and the pathogenesis of SARS-CoV-2Diagn Pathol1520208532665025 36InciardiRMAdamoMLupiLCaniDSDi PasqualeMTomasoniDCharacteristics"/>
 <result pre="36InciardiRMAdamoMLupiLCaniDSDi PasqualeMTomasoniDCharacteristics and outcomes of patients hospitalized for COVID-19 and" exact="cardiac disease" post="in Northern ItalyEur Heart J4120201821182932383763 37ShiSQinMCaiYLiuTShenBYangFCharacteristics and clinical significance"/>
 <result pre="PasqualeMTomasoniDCharacteristics and outcomes of patients hospitalized for COVID-19 and cardiac" exact="disease" post="in Northern ItalyEur Heart J4120201821182932383763 37ShiSQinMCaiYLiuTShenBYangFCharacteristics and clinical significance"/>
 <result pre="patients hospitalized for COVID-19 and cardiac disease in Northern ItalyEur" exact="Heart" post="J4120201821182932383763 37ShiSQinMCaiYLiuTShenBYangFCharacteristics and clinical significance of myocardial injury in"/>
 <result pre="clinical significance of myocardial injury in patients with severe coronavirus" exact="disease" post="2019Eur Heart J.4120202070207932391877 38BilalogluSAphinyanaphongsYJonesSIturrateEHochmanJBergerJSThrombosis in hospitalized patients with COVID-19"/>
 <result pre="of myocardial injury in patients with severe coronavirus disease 2019Eur" exact="Heart" post="J.4120202070207932391877 38BilalogluSAphinyanaphongsYJonesSIturrateEHochmanJBergerJSThrombosis in hospitalized patients with COVID-19 in a"/>
 <result pre="of the coagulation systemEur J Haematol202010.1111/ejh.13501 40Al-SamkariHKarp LeafRSDzikWHCarlsonJCTFogertyAEWaheedACOVID-19 and coagulation:" exact="bleeding" post="and thrombotic manifestations of SARS-CoV-2 infectionBlood136202048950032492712 41MezalekZTKhibriHAmmouriWBouaouadMHaidourSHarmoucheHCOVID-19 associated coagulopathy"/>
 <result pre="coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infectionBlood136202048950032492712 41MezalekZTKhibriHAmmouriWBouaouadMHaidourSHarmoucheHCOVID-19 associated" exact="coagulopathy" post="and thrombotic complicationsClin Appl Thromb Hemost2620201076029620948137 42MonteilVKwonHPradoPHagelkruysAWimmerRAStahlMInhibition of SARS-CoV-2"/>
 <result pre="coagulopathy and thrombotic complicationsClin Appl Thromb Hemost2620201076029620948137 42MonteilVKwonHPradoPHagelkruysAWimmerRAStahlMInhibition of SARS-CoV-2" exact="infections" post="in engineered human tissues using clinical-grade soluble human ACE2Cell1812020905913e732333836"/>
 <result pre="49YamamotoMMatsuyamaSLiXTakedaMKawaguchiYInoueJIIdentification of nafamostat as a potent inhibitor of middle east" exact="respiratory" post="syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based"/>
 <result pre="of nafamostat as a potent inhibitor of middle east respiratory" exact="syndrome" post="coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell"/>
 <result pre="cases of treatment with nafamostat in elderly patients with COVID-19" exact="pneumonia" post="who need oxygen therapyInt J Infect Dis96202050050232470602 51CortegianiAIppolitoMIngogliaGIozzoPGiarratanoAEinavSUpdate I."/>
 <result pre="double-blind, placebo-controlled, multicentre trialLancet39520201569157832423584 58AntinoriSCossuMVRidolfoALRechRBonazzettiCPaganiGCompassionate remdesivir treatment of severe Covid-19" exact="pneumonia" post="in intensive care unit (ICU) and Non-ICU patients: clinical"/>
 <result pre="62SheahanTPSimsACZhouSGrahamRLPruijssersAJAgostiniMLAn orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway" exact="epithelial" post="cell cultures and multiple coronaviruses in miceSci Transl Med125412020eabb588332253226"/>
 <result pre="and chemokine profile in relation to the severity of coronavirus" exact="disease" post="2019 (COVID-19) in ChinaJ Infect Dis2225202074675432563194 66XuXHanMLiTSunWWangDFuBEffective treatment of"/>
 <result pre="70EckerleLDBeckerMMHalpinRALiKVenterELuXInfidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by" exact="complete" post="genome sequencingPLoS Pathog62010e1000896 71KorberBFischerWMGnanakaranSYoonHTheilerJAbfaltererWTracking changes in SARS-CoV-2 spike: evidence"/>
 <result pre="vaccine: a dose-escalation, open-label, non-randomised, first-in-human trialLancet39520201845185432450106 79YangYNunesFABerencsiKFurthEEGonczolEWilsonJMCellular immunity to" exact="viral" post="antigens limits E1-deleted adenoviruses for gene therapyProc Natl Acad"/>
 <result pre="in part by grants from NIH, National Heart, Lung and" exact="Blood" post="Institute ( 10.13039/100000050NHLBI R01 HL132401, R01 HL151737, and S10"/>
</results>
